NEW YORK, July 11 – Genzyme Diagnostics no longer has first offer rights to future technologies developed by Syn-X Pharma, following an agreement that resolves previous disputes between the two companies.

In a statement issued on Tuesday, Genzyme and Syn-X announced that Genzyme would continue to develop a stroke panel called NeuroTrak, while Syn-X would retain rights to future royalty payments based on product sales.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.